partners

In a significant stride for retinopathy treatment, the NeoVasculoStop consortium has successfully reached the milestone of Month 30 entitled “Identification of the Two Best Inhibitors.” Correspondingly, EYE1118 has been selected as an efficient promising lead compound and EYE1090 as the follow up molecule. This achievement marks a critical phase in the project aimed at developing advanced inhibitors for targeted disease treatment.

We are optimistic about the future applications of these results in treating a complex group of diseases.